March 2026
Includes: New characteristics of aggressive prostate cancer identified, how to treat recurring prostate cancer, apalutamide vs. darolutamide in mCSPC,
Monthly Supporter
Your Monthly Gift Brings Hope and Support to Families Facing Prostate Cancer PROSTAID Calgary is a community of men, families, […]
Introduction to PARP-Inhibitors and their role in Cancer Treatment
Dr. Geoffrey Gotto, Urologic Oncologist at the Southern Alberta Institute of Urology, joins us again to explain PARP inhibitors and their importance in modern treatment of cancer cells.
February 2026
Includes: Spotlighting the Top 10 FDA Oncology Approvals in 2025, CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction,
January 2026
Includes: Prostate cancer cells thrive in bone tissue, Top 10 Urology Times prostate cancer articles of 2025, Reversing treatment resistance in prostate cancer,
December 2025
Includes: Focused ultrasound offers safe and effective prostate cancer treatment, Neuromodulation therapy for erectile dysfunction after radical prostatectomy,
A History of Cancer Clinical Trials in Canada
Dr. Fedir Razumenko from the University of Calgary joins us for a look at the progression of cancer treatment in Canada, comparing stats from the 1920s to today and how today’s treatments were forged by brave and competitive voices throughout the country.
November 2025
Includes: Drug combo cuts risk of death in advanced prostate cancer by 40%, targeting enzymes to weaken cancer cells could supercharge treatment,
Introduction to PARP Inhibitors
Dr. Tarek Bismar from the Prostate Cancer Centre joins us again to talk about PARP inhibitors and their role in cancer treatment. He shows their activity in cancer cells, synergy with other cancer therapies, and how people respond depending on their cancer type.
October 2025
Includes: Tailgating With Dr. Digital 2025, Prostate Cancer Stage Increasing, Survival Gains Slowing in the United States, protecting against erectile dysfunction,